Trial reportArthritis & rheumatology (Hoboken, N.J.)2025
Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.
Trial report in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03298061 (Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Monoclonal antibodies targeting IL-5/5R or IL-4/13 pathways in eosinophilic myocarditis: a single-centre experience and systematic literature review.European heart journal. Cardiovascular pharmacotherapy · 2026Pooled it
- Advances in the treatment of eosinophilic granulomatosis with polyangiitis.Nature reviews. Rheumatology · 2026Review
- Review
- Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES.The journal of allergy and clinical immunology. Global · 2026Article
- Article
- Anesthetic Management of Eosinophilic Granulomatosis with Polyangiitis: A Narrative Review with an Illustrative Case in Cardiac Surgery.Journal of personalized medicine · 2026Review
- Validation of the 2022 ACR/EULAR classification criteria for eosinophilic granulomatosis with polyangiitis in a Chinese cohort.Clinical rheumatology · 2026Article
- Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan.Scientific reports · 2026Article
- Glucocorticoid discontinuation in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: associations with tapering patterns and initiation timing.Frontiers in immunology · 2026Article
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study.Frontiers in allergy · 2026Article
- High Disease Burden and Oral Corticosteroid Use in Patients with Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis: Country-Level Insights into Real-World Management in Europe.Journal of clinical medicine · 2025Article
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.Biomolecules · 2025Review
- Clinical updates of JAK inhibitors in cutaneous granulomatous diseases.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveEosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti-interleukin-5 biologic, for EGPA. This open-label extension (OLE) of MIRRA assessed long-term safety and OCS-sparing effects of mepolizumab.
methodsThe OLE (NCT03298061) was a multicenter study that enrolled patients from MIRRA who required OCS ≥5 mg/day up to six months after the end of MIRRA. All patients received mepolizumab 300 mg subcutaneously every four weeks plus standard of care until mepolizumab was discontinued or became approved and reimbursed for EGPA in the respective country. Key outcomes included adverse events (AEs) and use of OCS.
resultsOne hundred patients were enrolled in the OLE. Mean (SD) and median (min-max) exposure during OLE was 38.5 (27.0) and 27.0 (1.0-89.0) months. On-treatment AEs were experienced by 98% of patients (43% treatment related; most frequent: injection site reaction [10%]) and serious AEs by 38% of patients (6% treatment related) with no new safety signals versus MIRRA identified. Median (Q1-Q3) OCS dose decreased from 10.0 (7.8-15.0) mg/day at OLE baseline to 5.0 (0.0-10.0) mg/day at study exit. Proportion of patients using OCS >7.5 mg/day decreased from 75% at baseline to 32% at study exit; 28% of patients discontinued OCS.
conclusionLong-term use of mepolizumab to treat EGPA was well tolerated and resulted in sustained reductions in OCS use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.